Clinical Trials

360 enrolled

Neoplasms, Endometrial Neoplasms

NCT05564377 2026-05-27

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

2,900 enrolled

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms

NCT06619236 2026-05-27

RAINFOL-02

448 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07198074 2026-05-27

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

255 enrolled

Endometrial Neoplasms

NCT07213804 2026-05-27

FRAmework-01

1,080 enrolled

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Peritoneal Neoplasms

NCT07286266 2026-05-27

A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)

450 enrolled

Ovarian Neoplasms

NCT07286331 2026-05-27

A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)

600 enrolled

Endometrial Neoplasms

NCT06535607 2026-05-26

eVOLVE-02

GastrointestinalGynecologicHead & Neck

257 enrolled

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Uterine Cervical Neoplasms

NCT06843447 2026-05-26

MK-5909-003

Phase 1/2 Recruiting

460 enrolled

Ovarian Cancer Recurrent

NCT07061977 2026-05-26

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

336 enrolled

Locally Advanced Cervical Adenocarcinoma

NCT07214779 2026-05-26

MAESTRA 2

466 enrolled

Ovarian Neoplasms

NCT06102252 2026-05-22

Combination Chemotherapy of Paclitaxel and Carboplatin With or Without Anthracycline as Aneo Adjuvant Treatment in Advanced Endometrial Carcinoma

Phase NA Completed

60 enrolled

Endometrial Neoplasms

NCT06161025 2026-05-22

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2/3 Recruiting

860 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06952504 2026-05-22

TroFuse-033

1,123 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Endometrial Neoplasms

NCT07216703 2026-05-22

TroFuse-036

1,023 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Cervical Neoplasms

NCT07604766 2026-05-22

RAINFOL-02

82 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05819892 2026-05-20

Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer

21 enrolled

Endometrial Neoplasms

NCT06340568 2026-05-20

Fern-EC-01

480 enrolled

Endometrial Neoplasms

NCT07044336 2026-05-20

Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

700 enrolled

Neoplasm Metastasis, Uterine Neoplasms, Endometrial Neoplasms

NCT07042802 2026-05-18

A Phase Ib/Ⅱ Clinical Trial of LBL-024 Combined With Paclitaxel in Patients With Platinum-resistant Ovarian Cancer

Phase 1/2 Recruiting

110 enrolled

Ovarian Neoplasms

NCT05255653 2026-05-15

RAINBO

Phase 2/3 Recruiting

1,615 enrolled

Endometrial Neoplasms

NCT06840886 2026-05-14

A Study of PHST001 in Advanced Solid Tumors

CNSGastrointestinalGynecologic

272 enrolled

Ovarian Neoplasms, Central Nervous System Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT01081951 2026-05-13

Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer

Phase 2 Active not recruiting

162 enrolled 15 charts

Phase 2 Active not recruiting

Ovarian Neoplasms

NCT04274426 2026-05-13

MIROVA

136 enrolled

Phase 1 Active not recruiting

Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma

NCT03932409 2026-05-08

FIERCE

45 enrolled

Endometrial Neoplasms

NCT06023862 2026-05-06

DOVE

198 enrolled

Uterine Cervical Neoplasms, Ovarian Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms, Adenocarcinoma, Clear Cell

NCT06989112 2026-05-06

DE-01

600 enrolled

Phase 2 Not yet recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Neoplasms, Endometrial Neoplasms

NCT07265739 2026-05-06

Losartan and Paclitaxel in Platinum Resistant Ovarian Cancer

27 enrolled

GastrointestinalGynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT04034251 2026-05-05

Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis

Phase 2 Terminated

12 enrolled 18 charts

Adenocarcinoma, Peritoneal Neoplasms, Stomach Neoplasms

NCT05173987 2026-05-05

KEYNOTE-C93

280 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Endometrial Neoplasms

NCT06434610 2026-05-05

A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.

90 enrolled

Platinum-resistant Recurrent Ovarian Cancer

NCT01167712 2026-05-04

Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

692 enrolled 11 charts

Brenner Tumor, Fallopian Tube Neoplasms

NCT02446600 2026-05-04

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

579 enrolled 17 charts

Phase 1/2 Active not recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03393884 2026-05-04

OVATION 2

130 enrolled

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT03740165 2026-05-04

KEYLYNK-001

Phase 3 Completed

1,367 enrolled 29 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT03914612 2026-05-04

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

813 enrolled 16 charts 1 FDA

GynecologicSarcoma

Carcinosarcoma, Endometrial Neoplasms

NCT05739981 2026-05-04

MRD

Phase 1/2 Recruiting

30 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06915025 2026-05-04

OVATION-3

500 enrolled

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07564141 2026-05-04

RAINFOL™-07

688 enrolled

Ovarian Neoplasms

NCT01081262 2026-04-30

Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer

50 enrolled 13 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05613088 2026-04-30

A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2 Completed

106 enrolled 23 charts

Phase 2 Active not recruiting

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00977574 2026-04-29

Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

349 enrolled 11 charts

GynecologicSarcoma

Endometrial Adenocarcinoma

NCT02502266 2026-04-29

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

Phase 2/3 Active not recruiting

582 enrolled 21 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07545460 2026-04-22

A Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer

404 enrolled

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT03556839 2026-04-21

BEATcc

Phase 3 Completed

410 enrolled

Carcinoma, Uterine Cervical Neoplasms

NCT06964009 2026-04-21

DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer

30 enrolled

Ovarian Neoplasms

NCT06828354 2026-04-20

A Study of SHR-A1811 in Subjects With Ovarian Cancer

300 enrolled

Ovarian Neoplasms

NCT06994195 2026-04-20

A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01)

384 enrolled

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT04615013 2026-04-16

NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer

GastrointestinalGynecologic

24 enrolled

Cervical Esophagus Adenocarcinoma

NCT04220827 2026-04-15

Paclitaxel for the Treatment of Gastric or Gastroesophageal Cancer

Phase 1 Active not recruiting

27 enrolled